2026 Biomedical Final Pitch Competition and Conference
May 23rd and 24th
Registration Deadline May 16th
Co-organizers:
Boston Capital Investment Club (BCIC)
Hong Kong Science and Technology Parks Corporation (HKSTP)
You are invited to the 2026 Biomedical Pitch Competition Final Pitch Event, connecting biomedical start-ups with investors and other business accelerator resources. 17 finalists and 4 pitch-only selected high-quality teams, ranging from early-stage to mid-stage and from pharmaceutical to medical device and diagnostics, will present their companies in public.
What to Expect:
- High-caliber Audience: 200+ Angel/VC funds and industry leaders seeking groundbreaking biomedical solutions.
- Diverse Opportunities: Explore potential direct investments, licensing partnerships, and valuable collaborations.
- Media Exposure: Gain widespread recognition through media coverage reaching 20,000+ viewers.
A Track Record of Impact: Recent Success Stories
- Leveragen, a winning team from our 2024 competition, has announced a strategic collaboration with Daiichi Sankyo as of 2026
- One 2025 winner executed a NewCo spin-off deal in January 2026
- One 2023 winner successfully secured follow-on funding at the end of 2025
| 2025 Pitch Competition HighlightsEpigenic raised $60 million successfully (https://bcicglobal.org/affinity_raised_fund/)Groovy raised funding (https://bcicglobal.org/groovy_secured_funding/)One NewCO deal in 2026 January |
| 2024 Pitch Competition HighlightsRapafusyn raised $44 million successfully in USA (https://bcicglobal.org/rapafusyn_44mil/)Agilis secured $10 million successfully from a Singapore family office (https://bcicglobal.org/agilis_raised_10mill/)GV20 secured funding of over $30 million successfully (https://bcicglobal.org/dv20_secured_funding/) Affinity secured funding of $55 million（https://bcicglobal.org/affinity_raised_fund/）ImmViral filed for IPO(https://bcicglobal.org/immviral_file_ipo/)Leveragen announced collaboration with Daiichi Sankyo in 2026 |
| 2023 Pitch Competition HighlightsMyrobalan raised $24 million successfully in the US within 5 months after participating in the pitch competition. (https://bcicglobal.org/myrobalan-therapeutics-secures-funding-of-24-million/)Two startups raised $2mil and $2mil separately.At least one startup landed in AsiaA company secured follow-on funding at the end of 2025 |
| 2022 Pitch Competition HighlightsAmytrx has raised $18 millionARIZ Precision Medicine has raised $3 millionBiostage has raised $5 millionAt least two startups landed in Asia |
Date:
| Day 1 Final Pitch Day | May 23rd Saturday 8:30am – 5:30pm |
| Day 2 Morning Conference | May 24th Sunday 9:00am- 12:30 |
Venue: Tickets are required for Onsite Attendants
Fish & Richardson P.C Conference Room (Floor 17th)
1 Marina Park Drive, Boston, MA 02210
Agenda:
Format:
In-Person: Limited capacity; reserved for approved guests and ticket holders.
Virtual: Open to all registered online attendees.
Registration Deadline: May 16th
Please register by scanning the QR Code to register
https://bcic.ticketspice.com/2026-biomedical-final-pitch-and-conference
Please send any questions via email: info@bcicglobal.org
Co-organizers and Sponsors
| Name | Description |
| Boston Capital Investment Club (BCIC) | The Boston Capital Investment Club (BCIC) is a Massachusetts-registered non-profit organization serving nearly 10,000 professionals in finance, venture capital, and various technology industries. Beyond being a Boston-centered platform, the BCIC has grown to facilitate nationwide and international knowledge exchange across healthcare, finance, and related fields. Since 2022, the organization has hosted annual biomedical pitch competitions, empowering startups to secure over $300 million in collective funding.https://bcicglobal.org/ |
| Hong Kong Science and Technology Parks Corporation (HKSTP) | With a 20-year history of transforming lives through innovation, technology and entrepreneurship, Hong Kong Science and Technology Parks Corporation (HKSTP) has been propelling success for the most creative minds and innovators around the globe, accelerating ambitions and delivering positive impact from Hong Kong to the Greater Bay Area and the world. As an advocate for the innovative spirit, we strive to cultivate a diverse talent pool, connect research to innofacturing through “new industrialisation”, and create a well-established I&T ecosystem that bridges innovators with high-potential partners and investors for ideas to grow and thrive.https://www.hkstp.org/ |
| Fish & Richardson P.C. | As the leading IP law firm, we help innovators change the world through our unmatched litigation, prosecution, and post-grant experience across venues and prosecution needs. We touch more PTAB cases, IP appeals, and utility patents than anyone else, and no national firm handles more district court patent cases. Many of our 450+ attorneys and technology specialists are also scientists who are as comfortable in a lab or cleanroom as a courtroom or patent office. We’re ready to hit the ground running to support your innovations, while distilling our vast technical and legal knowledge to resonate with business leaders or juries. You can be confident in every Fish lawyer in your corner because we intentionally build talent from the ground up and share knowledge generously and eagerly across the firm, leading to faster, fuller insights for you. Visionaries across eras have trusted us to protect their IP — from Alexander Graham Bell to today’s largest phone makers — and we’re ready to help build your IP strategy today with tomorrow in mind. Let’s change the world together. |
| Shanghai InnoStar | Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar), was established in 2010. As a leading contract research organization, we adhere to the core values of “Science orientated, Quality first, Integrity & dedication, Win-win cooperation”, and strive for innovative and reputational services with high quality and excellence. Over the past decade, InnoStar has successfully passed GLP inspections by various national and international authorities, including US FDA, and received the GLP certification from the National Medical Products Administration (NMPA), OECD GLP certification GLPmonitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. Our business scope covers screening and discovery services, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, biomarkers and translational research. InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710). |
| Porton Pharma Solutions Ltd | Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages. |
| PanaCRO | PanaCRO is a full-service clinical CRO founded in 2004, helping global biotech and biopharma companies accelerate clinical development in China. With 500+ employees, coverage across 20+ provinces, collaboration with 800+ research sites, and experience supporting 200+ customers and 200+ clinical trials, PanaCRO provides end-to-end solutions from pre-IND/IND strategy and regulatory support to investigator-initiated trials (IITs), Phase I–III studies, NDA/BLA registration, and post-market real-world studies. With strong expertise in oncology, autoimmune diseases, infectious diseases, metabolic disorders, CNS, ophthalmology, and vaccines, PanaCRO combines deep local regulatory knowledge with international ICH-GCP standards to deliver efficient, high-quality clinical execution. As a trusted partner for innovative drug development, PanaCRO helps sponsors navigate China’s clinical and regulatory landscape with speed, quality, and confidence |
| Simcere Pharmaceutical Group | Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company with capabilities in R&D, production and professional marketing. It primarily focuses on the therapeutic areas of oncology, nervous system, autoimmune and antiinfection, with proactive forward-looking layout of disease areas that have significant clinical needs in the future, aiming to achieve the corporate mission of “providing today’s patients with medicines of the future”. Driven by its in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many MNC, innovative companies, research institutes and clinical centers. In addition, Simcere has established several R&D innovation centers around the world. One of the innovation centers is Boston Innovation Center, located in Cambridge. |
Judges for the final pitch competition
- Hong Kong Science and Technology Parks Corporation (HKSTP)
- Northern Light Venture Capital (NLVC)
- TCG Crossover
- RA Capital
- Chugai Venture
- Kendall Capital Partners
- PagodaTree Partners
- Eisai Innovation, Inc
- HM Capital
Media Partners
- Deep Blue
- SaiBaiLan
- E Drug
- Drug Times
- Gene Online
- Page Executive
Appreciation List for helping to promote this event
| · Harvard Life Lab · Harvard Innovation Labs · Harvard Wyss Institute · Harvard Medical School CSSA · Ohio State University College of Pharmacy Innovation Center · Pittsburg University Healthcare Incubator · Stanford University Healthcare Innovation Lab – Stanford Pipeline · Nest.Bio · Netherlands Innovation Center (NIC) · Frees Fund · JJLake Asia Future Innovation Challenger · Dane Capital · Aquillius · Simcere Therapeutical · Blue Ocean Capital Group · Chinese Entrepreneurs Organization at Duke (DukeCEO) · Penn Quakers Venture Club- Fish & Richardson· InnoStar · Porton · 闻药事 | · Yale Venture Club · The Hopkins Club for Innovation and Entrepreneurship · Asia America Innovation Alliance (AAIA) · GeneOnline · Life-Science Entrepreneurship and Plus (LEAP) · Huazhong University of Science and Technology (HUST) Boston Alumni Association · Tongji Medical College of HUST Boston Chapter · YuanBio Venture Capital · AAEA · PagodaTree Partners · AbbVie Ventures · F Prime · Amgen Venture · TOP Innovation Districts Lab · Greenberg Traurig · Baker Mckenzie · The Chinese Antibody Society (CAS) – Berkley QB3- Startup Boston· 博药 · 前途汇· Biolink | · VIVA · Medicilon · ATLATL · Xingu Chuangfu · Alliance of Venture and Entrepreneurs Organization for Chinese Students Alumni at Harvard · Slush China · Danen Capital · Association d’Incubateur Franco-Chinois (AIFC) · Brandeis Impact · Chinese Entrepreneurs Organization · CuBio Innovation Center · HiMed · HuaSu Future · Eisai Innovation Inc · Regent Advisors · Enterprise Singapore · Massachusetts Biomedical Initiatives (MBI) · K2 Venture Partners· Singapore Economic Development Board (EDB)· Saudi Aribia NEOM Biotech Investment· P4 Precision Medicine Accelerator（UK） |
17+4 Finalists and Roadshow Only teams
